"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Multiple myeloma is a form of blood cancer that p"...
The maximum radiation activity of the I-131 component of the BEXXAR therapeutic regimen, administered to 4 patients, were doses calculated to deliver between 85 cGy and 88 cGy total body irradiation. The incidence of NCI Grade 4 cytopenias was increased in these 4 patients compared to patients who received the recommended therapeutic dose for the BEXXAR therapeutic regimen.
Last reviewed on RxList: 9/27/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Bexxar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.